Mississippi’s Synthetic Kratom Restrictions: Withdrawal Is Treatable

Understanding 7-OH, pseudoindoxyl, and your treatment options

If you have been using 7-OH tablets, shots, or other concentrated kratom products and suddenly cannot obtain them, you may be frightened about what happens next. Physical dependence can develop, and stopping may cause opioid-like withdrawal. You deserve compassionate medical care and a plan for recovery. [1, 4]

What Mississippi’s restrictions actually mean

Mississippi’s HB 1077 took effect July 1, 2025. It prohibits sales of products that fail the state’s kratom definition, which excludes synthesized kratom alkaloids and synthesized metabolites. Compliant products must meet both a 7-hydroxymitragynine limit of no more than 1% of total alkaloids and a limit of 0.5 mg per container. Sales to people under 21 are prohibited, and cities and counties may impose broader bans. This is not a newly enacted statewide ban on every form of botanical kratom. [2]

7-hydroxymitragynine, commonly called 7-OH, occurs at low levels in botanical kratom; concentrated or chemically enhanced products can deliver very different exposures. Mitragynine pseudoindoxyl, sometimes called “pseudo,” is another potent opioid-active compound. Mississippi health officials have warned about both. [1]

An October 22 Mississippi Today article describes proposals for tougher restrictions. Separately, an October 14 federal notice proposes Schedule I controls for 7-OH and pseudoindoxyl above specified thresholds. That federal notice is a proposed action, with an order to be published on or after November 13, 2026; it should not be described as an already effective new federal 7-OH ban. State and federal rules are separate. [3, 5]

What does opioid withdrawal feel like?

Withdrawal occurs when the body has adapted to a substance and its use stops or drops substantially. Symptoms can include anxiety, agitation, trouble sleeping, sweating, yawning, watery eyes, runny nose, muscle aches, goosebumps, enlarged pupils, abdominal cramps, nausea, vomiting, and diarrhea. [4]

For concentrated 7-OH and related products, timing and severity vary with ingredients, amount, frequency, and other substance use. There is no reliable universal home-detox timetable. Physical dependence alone does not establish an opioid use disorder; an evaluation also considers loss of control, cravings, harms, and daily functioning. [6, 7]

Treatment options: different medicines serve different purposes

At Turned Leaf Psychiatry, a treatment discussion can address withdrawal relief, cravings, mental health, and longer-term recovery. Medication selection requires an individual evaluation. These options are not interchangeable, and not every patient needs buprenorphine or long-term medication. Specific products and injections depend on clinical eligibility, practice availability, pharmacy access, and coverage.

Buprenorphine alone (often called Subutex)

Buprenorphine can reduce withdrawal and cravings and support ongoing opioid use disorder treatment. Subutex is a discontinued U.S. brand; generic sublingual buprenorphine remains available. The buprenorphine-only formulation is selected for specific clinical circumstances. [6, 8]

Suboxone and Zubsolv

Both contain buprenorphine plus naloxone. Suboxone is commonly supplied as film; Zubsolv is a sublingual tablet. Naloxone discourages injection misuse. Starting buprenorphine too soon can trigger precipitated withdrawal, a sudden worsening of symptoms. Initiation must follow a clinician’s plan. [6, 7]

Clonidine

Used off-label to ease symptoms such as sweating, agitation, and a racing stress response. It does not provide the same craving control or ongoing treatment as buprenorphine. Blood pressure and pulse require monitoring. [4, 15]

Lucemyra (lofexidine)

A non-opioid medicine FDA-approved to reduce withdrawal symptoms during abrupt opioid discontinuation in adults, for up to 14 days. It can cause low blood pressure, slow pulse, fainting, sedation, and heart-rhythm concerns. It is not a stand-alone treatment for opioid use disorder. [10]

Oral naltrexone and IM Vivitrol

Naltrexone blocks opioid effects and is used after detoxification to help prevent return to opioid use. Vivitrol is a monthly intramuscular naltrexone injection. Neither treats active withdrawal. Starting too soon can cause severe precipitated withdrawal. Labels recommend at least 7–10 opioid-free days after short-acting opioids; vulnerability can persist up to two weeks after buprenorphine or methadone. With novel kratom products, the prescriber must assess readiness individually. [11, 12]

Brixadi and Sublocade

These are long-acting buprenorphine injections for opioid use disorder. Brixadi comes in weekly and monthly formulations; Sublocade is monthly. Both are administered under the skin (subcutaneously). Brixadi is not an intramuscular injection. Product-specific initiation and certified-program requirements apply. [6, 13]

What about newer and emerging approaches?

Evidence for treating concentrated 7-OH dependence is developing. A 2026 retrospective series involving nine patients reported improvement with buprenorphine using standard or low-dose initiation. This is encouraging early evidence, not proof that one protocol fits everyone. Low-dose initiation is a clinician-directed, off-label approach; it should not be improvised at home. [7]

Prescription nerve-stimulation devices, such as NSS-2 Bridge, have FDA authorization as aids for opioid withdrawal symptoms. They are adjuncts, with more limited evidence than established medication treatment, and do not replace ongoing recovery care. A clinician can discuss whether a referral is appropriate. [14]

Other supportive care may include fluids and medicines for nausea, diarrhea, or aches when appropriate. Methadone is another established treatment for opioid use disorder, generally provided through a certified opioid treatment program; patients needing that option can be referred. Withdrawal management should connect to ongoing care rather than end when the physical symptoms improve. [4, 6]

How Turned Leaf Psychiatry can help

Contact Turned Leaf Psychiatry to request an assessment for kratom, 7-OH, or opioid-related withdrawal. Tell the office the exact product, the amount and frequency used, when you last used it, and what symptoms you are having. Bring a photograph of the packaging and a complete medication list.

An evaluation can help determine whether outpatient treatment is appropriate, whether a higher level of care is needed, and which medication or referral fits your needs. Treatment planning can also address co-occurring anxiety, depression, sleep problems, and relapse prevention. Turned Leaf Psychiatry serves patients physically located in Mississippi.

Buprenorphine and other sedating medications require careful review. Tell your clinician about alcohol, benzodiazepines, gabapentin, sleep medicines, and other substances. Do not add sedatives or abruptly stop a prescribed benzodiazepine on your own. [9]

When to seek urgent help

Seek urgent medical care for persistent vomiting, inability to keep fluids down, fainting, confusion, severe dehydration, or significant symptoms during pregnancy. Call 911 for slowed or stopped breathing, inability to wake up, seizures, chest pain, or an immediate threat to safety. Unresponsiveness and slow breathing suggest overdose or another emergency, not ordinary withdrawal.

Keep naloxone available and make sure someone knows how to use it. After stopping opioids, tolerance decreases; returning to a previously used amount can cause a fatal overdose. Do not try to overcome the blocking effects of naltrexone or Vivitrol. [11, 12]

You do not have to wait until withdrawal becomes unbearable to ask for help. A medical assessment can be the first step toward feeling better and building a safer, more stable recovery.

Educational information only. This article does not provide a home-detox regimen or guarantee a prescription. Legal information is current as reviewed November 4, 2026; treatment requires individual assessment.

Request an appointment or call (601) 494-5503.

Sources and further reading

Recent-source window: October 14–November 4, 2026. The two dated sources below include one Mississippi news article and one official federal notice. The withdrawal overview is an additional patient-education article.

[3] Mississippi Today — “After Ole Miss student deaths, Mississippi lawmakers eye tougher restrictions on kratom.” October 22, 2026.

[5] Federal Register — “Temporary Placement of 7-Hydroxymitragynine and Mitragynine Pseudoindoxyl Above a Specified Threshold in Schedule I.” October 14, 2026. Proposed amendment; notice of intent.

[4] MedlinePlus / National Library of Medicine — “Opiate and opioid withdrawal.” Patient overview of symptoms, complications, and treatment.

[1] Mississippi State Department of Health — Health alert on kratom and synthetic alkaloid products (2025).

[2] Mississippi Legislature — HB 1077 (2025), as sent to governor; effective July 1, 2025.

[6] FDA — Information about Medications for Opioid Use Disorder (MOUD).

[7] “Buprenorphine for the Management of 7-Hydroxymitragynine (7-OH) Use: A Retrospective Case Series.” PubMed PMID 42225057 (2026).

[8] SAMHSA — TIP 63: Medications for Opioid Use Disorder. Used for formulation history.

[9] SAMHSA — Buprenorphine Quick Start Guide.

[15] ASAM — National Practice Guideline (2015), withdrawal management.

[10] DailyMed — Lucemyra prescribing information.

[11] DailyMed — Vivitrol prescribing information.

[12] DailyMed — Naltrexone hydrochloride prescribing information.

[13] DailyMed — Brixadi prescribing information.

[14] FDA — Marketing authorization of NSS-2 Bridge for withdrawal symptom relief. November 15, 2017.